Retention of islet cell function in patients with type 1 diabetes has been associated with lower HbA~1c~ levels and reductions in short- and long-term complications ([@B1],[@B2]). Several therapeutic approaches have been tried to preserve residual β-cell function in such patients. One approach, based on animal and human studies, is to optimize glycemic control as soon as possible after diagnosis. In vitro, resting β-cells are less immunogenic and more resistant to autoimmune damage than active β-cells ([@B3]). Tight metabolic control at the onset of type 1 diabetes can protect against insulitis in the BB rat ([@B4]--[@B6]) and insulin therapy in the NOD mouse has immunologic and metabolic effects ([@B7]). In humans, β-cell rest induced by closed-loop therapy shortly after the diagnosis of type 1 diabetes was reported to preserve β-cell function as assessed by C-peptide levels 1 year after diagnosis ([@B8]). The Diabetes Control and Complications Trial found that assignment to the well-controlled, intensively managed group slowed the rate of decline of stimulated C-peptide levels compared with that in the poorly controlled, conventionally treated group even when intensive metabolic control was initiated between 1 and 5 years after diagnosis ([@B2]).

With current technology, it may be possible to optimize glycemic control quickly after diagnosis with in-patient closed-loop control followed by home use of sensor-augmented pump (SAP) therapy. To test the hypothesis that use of advanced diabetes technologies within 7 days of onset of type 1 diabetes can preserve endogenous insulin production to a greater extent than current standard care of new-onset type 1 diabetes, we conducted a randomized trial comparing hybrid closed-loop control (HCLC) followed by home use of SAP therapy versus conventional management; the primary outcome was stimulated C-peptide levels 1 year after diagnosis.

RESEARCH DESIGN AND METHODS {#s1}
===========================

The study protocol, listed on [www.clinicaltrials.gov](http://www.clinicaltrials.gov) (NCT00760526), was approved by institutional review boards at the five clinical centers. Written informed consent was obtained from adult patients and parents/guardians of minor patients, who themselves also provided written assent. Major eligibility criteria included age 6 to \<46 years, clinical diagnosis of type 1 diabetes, and initiation of insulin therapy within the prior 7 days. Eligible participants were randomized to the intensive group or usual-care group in a 2:1 ratio, stratified by clinical center and the presence of diabetic ketoacidosis (DKA) ([@B9]). GAD, islet-cell antigen-512, insulin, and zinc transporter 8 antibodies were measured at baseline, and if these were negative islet cell antibodies, they were measured by indirect immunofluorescence at the core TrialNet laboratories (Universities of Colorado and Florida, respectively). Since autoantibody results were not available at the time of randomization, it was decided a priori that only participants who were antibody-positive would be included in the primary analysis.

Intensive-treatment group {#s2}
-------------------------

The intensive group received HCLC using the Medtronic MiniMed system (Medtronic) ([@B10],[@B11]) as inpatients with a goal of achieving at least 72 h of HCLC, with a maximum of 96 h. The system consists of a subcutaneous glucose sensor and insulin pump which communicate wirelessly with a bedside computer running a proportional-integral-derivative algorithm. The proportional-integral-derivative algorithm has been previously described ([@B10]--[@B12]) but was modified to incorporate insulin feedback ([@B13]--[@B15]). The glucose set point was 110 to 120 mg/dL. Up to 20 min prior to each meal and snack, carbohydrates were counted, and a premeal bolus was given to cover ∼75--80% of the meal based on the participant's carbohydrate-to-insulin ratio. Participants could choose their meals and snacks. The full details and results of this therapy have been previously published ([@B16]).

During the hospitalization, intensive group participants were instructed on use of the Medtronic MiniMed Paradigm or Revel insulin pump, MiniLink transmitter, and Sof-sensor continuous glucose monitor (CGM) (all from Medtronic MiniMed, Inc.) to be used as an outpatient following discharge. Glucose meters and strips were provided to both treatment groups. Following hospitalization, intensively treated participants were expected to use the pump and CGM daily. CGM data were reviewed by clinical staff at 1, 2, 4, 6, and 8 weeks and then monthly, with additional data reviews as needed and treatment adjusted according to Diabetes Research in Children Network (DirecNet) study group guidelines ([@B17]).

Usual-care group {#s3}
----------------

Participants in the usual-care group received standard diabetes management as practiced at the participating diabetes treatment centers, including frequent telephone contacts to adjust the treatment regimen following discharge from the hospital by clinicians not involved in the management of participants in the intensive-treatment group. As in the intensive group, standard-care patients were seen as outpatients 2, 6, and 13 weeks after diagnosis and every 3 months thereafter. The aim of therapy was to achieve HbA~1c~ and blood glucose levels as close to normal as possible. There was no prohibition on use of an insulin pump or CGM if the physician believed that either or both would benefit from the participant's diabetes management.

Study procedures {#s4}
----------------

Both groups had a 90-min mixed-meal tolerance test (MMTT) at baseline once DKA, if present, was resolved; 2-h MMTTs were performed at 2 and 6 weeks and at 3, 6, 9, and 12 months. HbA~1c~ was measured at 3, 6, 9, and 12 months at a central laboratory. HbA~1c~ was also measured locally at 6 weeks and at 3, 6, 9, and 12 months. For the intensive-treatment group, the CGM, insulin pump, and home glucose meter were downloaded at each visit. For the usual-care group, glucose meters were downloaded at each visit, and a blinded Medtronic Guardian CGM (Medtronic MiniMed, Inc.) was worn for 3 days after each visit. Investigators were masked to the MMTT results.

Statistical methods {#s5}
-------------------

Primary outcome measure was the area under the stimulated C-peptide curve (AUC) of the 12-month MMTT. AUC was computed using a trapezoidal rule, which is a weighted sum of the C-peptide values over the 120 min. Sample size was computed for the number of antibody-positive participants required for the study. Log(mean C-peptide + 1) and root mean square error in the standard-treatment group were assumed to be 0.315 and 0.167, respectively, based on 90% CIs from prior studies ([@B18]). The corresponding geometric-like mean C-peptide value of 0.370 pmol/mL was calculated using the inverse transformation exponential (0.315) − 1. The expected geometric-like mean C-peptide value in the treatment arm was 0.370 \* 1.50 = 0.555 pmol/mL. With these estimates, a sample size of 63 was calculated to provide 85% power with a 5% one-sided type 1 error rate and a 2:1 treatment group allocation to detect a treatment group difference assuming the true relative difference between groups was 50%. Sample size was increased to 72 to account for antibody-negative individuals who would not be included in the primary analysis, incomplete follow-up, and anticipated noncompliance with the treatment regimen in the intensive group.

The primary analysis compared the difference between groups in the 2-h C-peptide using the log(AUC+1) transform in an ANCOVA model adjusting for sex, age, and baseline log(AUC+1) ([@B19]). Results are presented as the geometric-like mean, which was taken as the inverse transform noted above (x = exp (y) − 1) of the mean y = log(x + 1) transformed C-peptide values and their corresponding confidence limits ([@B18]). This was done for both AUC and peak C-peptide. One participant without 12-month MMTT data was not included in the primary analysis.

For tabulating CGM usage from sensor downloads, CGM was considered to be used when there was at least one sensor glucose value for the day. CGM indices (mean glucose, percent readings in target range, percent readings in hypoglycemic range, and coefficient of variation) were calculated giving equal weight to each of the 24 h of the day ([@B20]). At least 24 h of CGM data were required for calculating CGM indices. SAS 9.3 (SAS Institute) was used for analyses.

RESULTS {#s6}
=======

Between May 2009 and October 2011, the trial enrolled 71 individuals with type 1 diabetes; 68 had positive autoantibodies and were included in the primary analysis, with 48 assigned to the intensive group and 20 to the usual-care group. Analyzed participants ranged in age from 7.8 to 45.7 years, with all but three \<18 years old; 65% were male and 92% were white. For 72%, highest parental education was Bachelor's degree or higher ([Supplementary Table 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-1074/-/DC1)). DKA was present at diagnosis in 20 (29%) participants. Enrollment occurred within 6 days of diagnosis in all participants (mean 2.9 ± 1.6 days).

Visit completion {#s7}
----------------

The 12-month primary outcome visit was completed by all 68 participants (1 in the intensive group did not complete the MMTT). Visit completion for the six protocol-specified follow-up visits was 100% in the intensive group and 89% in the usual-care group ([Supplementary Fig. 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-1074/-/DC1)).

Intensive-treatment group {#s8}
-------------------------

HCLC was initiated 2--7 days after diagnosis of type 1 diabetes (mean 5.7 ± 1.2 days). Median duration of HCLC therapy was 71.3 h (interquartile range \[IQR\] 70.3--72.1 h; range 29.9--93.2 h). On initiation of HCLC, the mean glucose concentration was 240 ± 100 mg/dL. During the first day of HCLC, the median participant mean glucose concentration fell rapidly to 146 mg/dL (IQR 135--166) and was 138 and 139 mg/dL on days 2 and 3, respectively. By day 3, the median percentage of glucose values \>250 mg/dL and median percentage of glucose values \<60 mg/dL were \<1%. During the first 2 weeks of insulin pump and CGM use at home, the median participant mean sensor glucose level was 126 mg/dL (IQR 117--137), and the median percentage of values between 71 and 180 mg/dL was 85% (IQR 80--90%).

All but one participant in the intensive group used the insulin pump throughout the 12 months. Use of CGM gradually decreased over the 12 months ([Supplementary Fig. 2](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-1074/-/DC1)), with 6 of 48 participants discontinuing CGM altogether before 12 months. At 12 months, median CGM hours per week were 76 (IQR 24--120), with 33% of participants averaging ≥6 days per week and 50% averaging ≥5 days per week.

Usual-care group {#s9}
----------------

In the usual-care group, prior to 12 months, 15 of the 20 participants initiated insulin pump use, primarily after 6 months. Five used real-time CGM, although only two were still using CGM at 12 months.

C-peptide results {#s10}
-----------------

In the primary analysis of the 12-month MMTT results, the geometric mean (95% CI) of C-peptide AUC was 0.43 (0.34--0.52) pmol/mL in the intensive-treatment group and 0.52 (0.32--0.75) pmol/mL in the usual-care group (*P* = 0.49; [Table 1](#T1){ref-type="table"} and [Fig. 1](#F1){ref-type="fig"}). Geometric means of peak C-peptide concentrations were 0.53 (0.42--0.65) and 0.65 (0.40--0.95) pmol/dL, respectively; peak C-peptide concentrations were ≥0.2 pmol/dL in 37 (79%) and 16 (80%) in the intensive and usual-care groups, respectively. As seen in [Fig. 1](#F1){ref-type="fig"} and [Supplementary Table 2](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-1074/-/DC1), C-peptide results were similar between the two groups at all time points. A per-protocol analysis limited to the 22 participants in the intensive group using CGM at least 5 days/week and the 15 participants in the standard treatment group not using CGM at 12 months produced results similar to the intent-to-treat primary analysis, as did subgroup analyses based on participant characteristics ([Supplementary Table 3](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-1074/-/DC1)).

###### 

Outcome data at 12 months
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![Box plots for 2-h stimulated C-peptide AUC at each follow-up visit. The bottom and top of each box denote the 25th and 75th percentiles, respectively; the line inside the box denotes the median, and the dot is the geometric mean. The vertical axis is on a log(x + 1) scale.](4030fig1){#F1}

Other results {#s11}
-------------

HbA~1c~ levels were similar in both treatment groups throughout the study, reaching nadir values \<6.5% (\<48 mmol/mol) at 3 months and increasing gradually thereafter ([Fig. 2](#F2){ref-type="fig"} and [Supplementary Table 2](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-1074/-/DC1)). At 12 months, the mean HbA~1c~ was 7.4 ± 1.2% (57 ± 13 mmol/mol) in the intensive group and 7.3 ± 1.1% (57 ± 12 mmol/mol) in the usual-care group (*P* = 0.40). CGM-measured glucose indices were also similar in the two groups ([Table 1](#T1){ref-type="table"}, [Supplementary Table 2](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-1074/-/DC1), and [Supplementary Fig. 3](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-1074/-/DC1)), as was mean total daily insulin doses ([Fig. 3](#F3){ref-type="fig"}). Median BMI percentile at 12 months was 58 (IQR 39--81) in the intensive-treatment group and 62 (IQR 40--72) in the usual-care group.
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Adverse events {#s12}
--------------

Severe hypoglycemia, defined as an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions due to altered consciousness, occurred in one participant (two events, at 6 months while CGM was being used and 12 months after CGM had been discontinued) in the intensive group and in no participants in the usual-care group. There were no cases of DKA. During inpatient HCLC therapy, one subject had an anaphylactic reaction following his first dinner, presumably resulting from a peanut allergy, and received intravenous steroids. There were two cases of venous thrombosis related to the intravenous line that resolved without consequence. During follow-up, in the intensive group, one participant fainted following the 3-month MMTT, one had a skin infection related to the CGM sensor insertion, and one with a prior history of depression developed suicidal ideation. In the usual-care group, one participant was hospitalized for gastroenteritis and two developed depression and anxiety.

CONCLUSIONS {#s13}
===========

This study was undertaken to test the hypothesis that using advanced diabetes technologies to achieve tight glycemic control shortly after the diagnosis of type 1 diabetes would be beneficial in preserving β-cell function compared with current standards of care of new-onset type 1 diabetes as currently practiced at pediatric and adult diabetes treatment centers. The most important finding of the study was that the intensively treated participants who were randomized within the first week of diagnosis of type 1 diabetes to inpatient HCLC followed by outpatient SAP therapy did not have higher C-peptide levels at any time in the study when compared with a usual-care control group, even 2 weeks following closed-loop control. In evaluating the results, it is important to recognize that although the eligibility age range was 6 to \<46 years old, all but three of the participants were \<18 years old, and participants\' parents were generally well-educated. The sample size was too small for a meaningful assessment as to whether there was suggestion of benefit in any subgroup.

Our inability to demonstrate any differences in C-peptide preservation between the two groups may be related to the similar achievement of good glycemic control in both groups over the course of the 12 months, with the few days of HCLC shortly after the diagnosis of type 1 diabetes not producing an additive effect. It is important to note that patients in the usual-care group also sought to achieve and maintain optimal control of diabetes and that insulin pump and CGM use were not prohibited in this group if the physician and patient/parent decided on that course of management. Indeed, in the control group, 75% were using an insulin pump by 12 months, and 33% used CGM during the 12 months. In the intensive group, CGM use progressively decreased as the study progressed, and by 12 months, only 33% of the intensive group was using CGM ≥6 days per week. Thus, it is not surprising that the intensive group participants did not achieve any better glycemic control than the standard-care group as measured by HbA~1c~ or CGM-measured glucose indices.

It is noteworthy that C-peptide results in both groups appeared similar to control group data from prior TrialNet trials ([@B21]) as seen in [Supplementary Fig. 4](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-1074/-/DC1). These data suggest that the lack of a treatment group effect was not due to the control group in this study having better than expected C-peptide results. Our results are similar to the results seen in the Onset study, which also did not find a difference in HbA~1c~ or C-peptide levels after 1 year. In the Onset study, SAP therapy was compared with pump therapy alone in children and adolescents enrolled within 4 weeks from diagnosis of diabetes ([@B22]). As in our study, both groups similarly achieved good glycemic control, and there was no difference in C-peptide levels between groups after 1 year. Other previously reported smaller randomized trials of intensive insulin therapy at the onset of diabetes also did not show an improvement in C-peptide levels at 1 year ([@B23]--[@B28]).

Although HCLC therapy in the intensive group was successful in quickly overcoming initial hyperglycemia, it did not achieve the same level of glucose control within the first 2 weeks that was achieved in the study of Shah et al. ([@B8]), in which intravenous insulin was delivered using the Biostator for 2 weeks. We arbitrarily selected 3 days of hospitalization for closed-loop control rather than the 2 weeks as was previously done by Shah et al. ([@B8]), because we wanted to evaluate a therapy that could be practically implemented if we were successful. In the study by Shah et al. ([@B8]), the Biostator used blood (instead of subcutaneous) glucose measurements and intravenous (instead of subcutaneous) insulin, allowing them to have their subjects at a target glucose of 60--80 mg/dL ([@B8]), a target too low for us to safely achieve with current subcutaneous closed-loop therapy. Thus, it is possible that stricter glycemic control and/or longer duration of intensive therapy at diagnosis would show differences in preservation of C-peptide, but such a degree of glycemic control is not feasible with the technology used in this study. In addition, advances in insulin therapy and glucose monitoring since the time of the Shah et al. ([@B8]) study have made it much more difficult to achieve a separation in glycemic control between intensively treated and usual-care groups. Therefore, our study results do not necessarily refute the hypothesis that optimized glucose control from the time of diagnosis of type 1 diabetes can protect against β-cell destruction.

In summary, we did not find a benefit of HCLC therapy followed by SAP therapy in preserving β-cell function when initiated soon after the diagnosis of type 1 diabetes.
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